Vanda Pharma (VNDA) Reports Tasimelteon Met Primary Endpoint in Phase III
Go back to Vanda Pharma (VNDA) Reports Tasimelteon Met Primary Endpoint in Phase III| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.24 | 52 Week High | $18.00 | |||
| Open | $5.24 | 52 Week Low | $6.91 | |||
| Day High | $5.24 | P/E | N/A | |||
| Day Low | $5.24 | EPS | $-0.67 | |||
| Volume | 21,260 | |||||
